Comprehensive patent-claims and US patent landscape analysis for U.S. Patent 10,525,125 (mixed allergen oral therapy for multi-food allergy)
Which claims does US 10,525,125 cover for oral mixed allergen therapy?
U.S. Patent 10,525,125 claims oral immunotherapy methods for treating food allergy by administering a “mixed allergen composition” containing defined percentages (0.1% to 15% by weight each) of multiple “complete allergens,” including peanut, tree nuts, fish (white and/or pink), soy, wheat, sesame, egg, crustacean, and other listed food allergens. The independent scope is framed as method-of-treatment claims (not composition claims), but the method is defined by the composition that is orally administered.
What is the core independent claim 1 and why it is broad
Claim 1 covers:
- Treating a food allergy in a subject suffering from multiple food allergies
- Oral administration of a mixed allergen composition with:
- Walnut complete allergen: 0.1%–15% (wt/wt of composition)
- Peanut complete allergen: 0.1%–15%
- Hazelnut complete allergen: 0.1%–15%
- Soy complete allergen: 0.1%–15%
- White fish complete allergen and/or pink fish complete allergen: 0.1%–15%
- Weight stated as per total mass of the mixed allergen composition
Why this matters legally and technically:
- The claim requires a specific set of anchor allergens (walnut + peanut + hazelnut + soy + fish). That is a narrowing feature relative to “any multi-allergen mix,” but the numeric ranges and “and/or” fish selection are broad.
- “Complete allergen” is the key claim language. It typically implies a defined allergen preparation intended to preserve relevant epitopes, in contrast to partially hydrolyzed proteins or purified recombinant allergens. If “complete” is interpreted broadly by the intrinsic record, claim coverage expands; if “complete allergen” is limited to a specific processing standard, coverage narrows.
- The method claims do not require specific dosing schedules, patient ages, titration, or specific immunologic endpoints. That omission increases infringement risk for a wide range of oral mixed-allergen protocols that fit the composition definition.
What do dependent claims 2–9 add
Dependent claims expand the permissible allergen panel while preserving the same general 0.1%–15% by weight ranges:
- Claim 2: optionally adds sesame
- Claim 3: optionally adds crustacean
- Claim 4: specifies the fish components as white fish + pink fish together
- Claim 5: optionally adds egg white
- Claim 6: optionally adds wheat
- Claim 7: optionally adds almond
- Claim 8: optionally adds oat
- Claim 9: optionally adds pecan and/or pistachio
These are “panel expansion” dependencies. Operationally, they matter most in enforcement: if a competitor’s formulation includes any one of these optional allergens, the dependent claims can become directly relevant even if the base claim 1 is harder to read onto the exact allergen set.
How claim 10 changes the anchor set (single-allergy embodiments)
Claim 10 claims a related method for treating a subject with one food allergy by orally administering a mixed allergen composition containing:
- Peanut: 0.1%–15%
- Tree nut complete allergen: 0.1%–15%
- White and/or pink fish complete allergen: 0.1%–15%
Weight is again per total mass of the composition.
Key scope differences from claim 1:
- Claim 10 relaxes the requirement for specific tree nuts (walnut/hazelnut/almond) and uses the broader term “tree nut complete allergen.” That can sweep multiple tree nuts under one umbrella depending on claim construction.
- Claim 10 is structured to cover treatment of one allergy even though the administered composition contains multiple allergen components.
Dependent claims 11–16 further refine claim 10
- Claim 11: one food allergy is peanut
- Claim 12: one food allergy is fish
- Claim 13: one food allergy is tree nut
- Claim 14: optionally adds multiple specific tree nuts (walnut/almond/hazelnut/cashew/pecan)
- Claim 15: specifies fish as white + pink
- Claim 16: specifies crustacean as shrimp
From a claim-mapping perspective, claims 11–13 are straightforward patient-condition labels. Claims 14–16 can create strong “needle-to-thread” coverage if an accused product’s allergen panel matches one of these enumerated combinations.
How strong are US 10,525,125 claims against common “oral immunotherapy” design-arounds?
This patent’s enforcement leverage depends on how closely a competitor must match the claimed composition definition (anchor allergens + concentration ranges + “complete allergen” definition + fish type).
Design-around levers competitors can try
-
Remove one required anchor allergen
- Claim 1 requires walnut + peanut + hazelnut + soy + fish (white and/or pink).
- If a competitor’s mixed formulation excludes soy or excludes either walnut or hazelnut, claim 1 likely weakens.
- Claim 10 requires peanut + tree nut + fish, so omission of peanut or fish can also avoid that scope.
-
Change allergen concentration outside 0.1%–15%
- The numeric ranges are wide (15-fold in each component). A competitor can attempt to place at least one included allergen outside the range (below 0.1% or above 15%), but this can be difficult operationally if multiple allergens are present at consistent protein load targets.
- If a product uses a fixed dose format where component proportions vary by batch or mixing, the question becomes whether the “weight %” is met under the competitor’s specifications.
-
Use a different allergen preparation not meeting “complete allergen”
- This is often the most meaningful pharmaceutical IP lever.
- If “complete allergen” is limited in the specification to a particular preparation (for example, full-length proteins, specific extraction, minimal denaturation, or particular allergen processing), then a competitor using hydrolysates, recombinant fragments, or otherwise different allergen forms can avoid the claim without changing the overall panel.
-
Avoid fish type language
- The claims distinguish white fish and pink fish and provide an “and/or.”
- A competitor using different fish sources or species not falling into those categories can attempt to step outside the “white/pink” definition.
Why the claims remain difficult to avoid in practice
- The concentration ranges are broad.
- The allergen panel is not a single allergen or two allergens. The anchor set includes multiple common allergens used in multi-allergen oral immunotherapy products.
- If a competitor is already targeting cross-protection or broad desensitization across peanut/tree nut/fish, the claimed panel is likely to be operationally attractive.
What patent landscape surrounds multi-allergen oral immunotherapy in the US?
The US patent landscape for oral immunotherapy is dense and layered:
- Allergen source/preparation patents (what is “complete allergen,” how it is extracted/processed, mixtures of allergenic proteins)
- Dosing regimen patents (initiation, escalation, maintenance schedules)
- Method-of-treatment patents (treating multi-allergy patients, inducing tolerance, desensitization)
- Manufacturing and formulation patents (stability, delivery vehicles, dosing units)
- Regulatory exclusivity and label-protected claims for any approved oral immunotherapy products
For mixed allergen approaches, a recurring theme in the literature and enforcement is that claims frequently overlap at three levels:
- the list of allergens,
- the proportion ranges,
- the preparation definition (complete vs modified allergen),
with “method for treating” claims then tying those definitions to specific patient subsets (multi-allergy vs single allergy).
Key landscape questions that determine litigation risk
- Does an accused product use “complete allergen” preparations as defined in the patent’s specification?
- Does the accused product meet the required anchor set (walnut/peanut/hazelnut/soy/fish or peanut/tree nut/fish)?
- Are the weight percentages within 0.1%–15% for the relevant components?
- Are fish allergens the same “white”/“pink” categories used by the patent?
What is the likely claim-construction pressure point: “complete allergen”?
“Complete allergen” is the highest-impact term in the claim set because it is likely to control:
- whether immunogenic epitopes are preserved,
- whether allergens are full-length,
- whether specific processing is required,
- whether allergen content is measured as protein content vs total mass,
- and whether mixtures are prepared using a particular extraction protocol.
In mixed-allergen oral immunotherapy, competitors may use:
- native extracts,
- standardized allergen preparations,
- recombinant proteins,
- or partially hydrolyzed forms.
If the intrinsic record for US 10,525,125 defines “complete allergen” narrowly, the patent’s effective scope may be smaller than the numeric and list-based language suggests. If construed broadly, it becomes easier for enforcement to map a competitor’s manufacturing and product specifications to the claim.
How does the patent’s structure affect infringement analysis (method claims based on administered composition)?
Because the claims are method claims “comprising orally administering” a defined mixed allergen composition, infringement hinges on:
- product composition at the time of administration,
- and the clinician or sponsor’s treatment protocol in the US.
In practice, this creates two common litigation pathways:
- Direct infringement by the product sponsor/manufacturer for “offering and inducing” administration, depending on the claim and enforcement theory.
- Induced or contributory infringement arguments focused on manufacturing specifications and labeling that promote the administration of a composition fitting the claim.
The numeric ranges create a measurable standard:
- weight percent per total mass can be tested using formulation records, compositional assays, and batch release specifications.
What commercial “hot zones” does US 10,525,125 target?
The claim set maps to commercial strategies built around:
- broad multi-food desensitization in patients with co-existing allergies (claim 1),
- and single-allergy treatment using a mixed composition that includes other allergens as collateral desensitization (claim 10).
This is commercially relevant because:
- co-morbid peanut/tree nut/fish allergy populations are large enough to justify multi-allergen platforms,
- and mixed platforms reduce patient burden relative to sequential single-allergen oral immunotherapy.
Timeline and exclusivity: what likely matters next for freedom-to-operate?
The patent number indicates the assignee expects enforceable term beyond approval and commercialization. The practical freedom-to-operate question is whether US 10,525,125 expires before a competitor’s intended US launch date, and whether any continuation, related patents, or formulation-preparation patents extend the effective estate.
However, without the patent’s filing date, priority chain, and any related continuations, an accurate claim-by-claim expiration and exclusivity calendar cannot be produced from the information provided.
Key takeaways
- Claim 1 is anchored on a five-allergen mix: walnut, peanut, hazelnut, soy, and white/pink fish, each at 0.1%–15% by weight, for treating multi-food allergy.
- Claims 2–9 broaden the optional allergen panel (sesame, crustacean, egg white, wheat, almond, oat, pecan/pistachio) without changing the concentration framework.
- Claim 10 shifts to single-food allergy treatment while using a mixed composition anchored on peanut + tree nut + white/pink fish at 0.1%–15% by weight, with dependents labeling the specific allergy and adding specific tree nut variants.
- The enforcement battleground is likely “complete allergen” definition and whether a competitor’s allergen preparation and formulation specifications satisfy it, plus whether their anchor allergens and weight percentages match the claimed ranges.
FAQs
1) What is the fastest path to avoid claim 1 infringement?
Remove at least one required anchor allergen from the walnut/peanut/hazelnut/soy/fish set or shift that anchor allergen’s component concentration outside 0.1%–15% or use an allergen preparation that does not qualify as “complete allergen.”
2) Can claim 10 be infringed by treating peanut allergy with a mixed peanut/tree nut/fish composition?
Yes. Claim 10 covers treatment of one food allergy using a mixed composition containing peanut, tree nut, and white/pink fish. Dependent claim 11 labels peanut as the one allergy.
3) Do the claims require specific dosing schedules or clinical endpoints?
No. They define treatment by oral administration of a mixed allergen composition with specified component identity and concentration ranges.
4) Do the claims require both white fish and pink fish?
No for claim 1 and claim 10 because fish is “white and/or pink.” Claim 4 and claim 15 require both.
5) How do optional allergens in dependent claims change risk?
They expand coverage if a competitor includes those allergens. Even if an accused product matches claim 1’s anchor set, inclusion of sesame, crustacean, egg white, wheat, almond, oat, pecan/pistachio can bring additional dependent-claim coverage.
References
- U.S. Patent 10,525,125. (claim set as provided).
